Abstract: Phosphonoacetic acid derivatives and their use for treating degenerative joint disorders Compounds of the formula I ##STR1## are suitable for producing pharmaceuticals for the treatment and prophylaxis of degenerative joint disorders, of rheumatic disorders accompanied by cartilage breakdown, such as rheumatoid arthritis, joint trauma and chondrolysis as a consequence of prolonged immobilization of the joint, of inflammations, septic shock, disorders with impaired leukocyte adhesion, disorders caused by an elevated concentration of tumor necrosis factor alpha, such as cachexia or Crohn's disease.

Abstract: Compounds of formula I, ##STR1## wherein the substituents R.sub.1 -R.sub.4 and a have the given meanings and show an activity against inflammatory conditions.

Abstract: N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 1 beta is involved. It is used as a pharmaceutical.

Abstract: N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 1 alpha is involved. It is used as a pharmaceutical.

Abstract: The use of leflunomide for inhibiting interleukin 8 N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which interleukin 8 is involved. It is used as a pharmaceutical.

Abstract: N-(4-Trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide is an effective compound for preventing and treating disorders in which tumor necrosis factor alpha is involved. It is used as a pharmaceutical.

Abstract: Pharmaceutical for the treatment of skin disordersA compound of the formula I or II ##STR1## and physiologically tolerable salts of compound of the formula II are suitable for treatment of psoriasis.

Abstract: Novel substituted thiazoles of the formula I ##STR1## in which R.sup.1 is a saturated or unsaturated, straight-chain or branched C.sub.1 -C.sub.5 -alkyl group,R.sup.2 is a hydrogen atom or an alkyl radical having 1 to 3 carbon atoms,A is an intermediate chain of the formula--(CH.sub.2).sub.n --Y--CR.sup.3 R.sup.4 --; --CH.dbd.CR.sup.3 --(CH.sub.2).sub.m -- or --CH.dbd.N--O--(CH.sub.2).sub.n --whereY is a single bond, an oxygen or sulfur atom or a carbonyl group,R.sup.3 and R.sup.4 are identical or different and are a hydrogen atom or an alkyl radical having up to two carbon atoms, m is a number from 0 to 3 and n is a number from 1 to 4, andZ is a tetrazole or CN group, or a radical of the formula ##STR2## X is a hydroxyl group or a radical of the formula R.sup.5 O-- or R.sup.6 R.sup.7 N--, where R.sup.5 is a straight-chain or branched C.sub.1 -C.sub.4 -alkyl radical which is optionally substituted by hydroxyl, C.sub.1 -C.sub.3 -alkoxy or C.sub.1 -C.sub.3 -alkylamino,R.sup.6 and R.sup.

Abstract: The present invention relates to formulations containing unsaturated fatty acids for the synthesis of prostaglandins and hydroxy-fatty acids in biological systems and to the use of such formulations for the preparation of medicaments which are suitable for curing prostaglandin deficiencies in humans or animal, for example healing or preventing diseases of the gastro-intestinal tract.

Abstract: The antiaggregatory effect of phosphodiesterase inhibitors (A) and/or of cyclooxygenase inhibitors (B) is detected outside the human or animal body bysampling blood,addition of (A) and/or (B) to the blood sample--if not already present therein, in unchanged or in metabolized form, as a consequence of previous administration,where appropriate removal of the erythrocytes and leukocytes andinitiation--preferably by addition of an aggregation inducer--and measurement of the platelet aggregation,the method comprises (A) also being added--if only (B) has been administered or added up till then--or (B) also being added--if only (A) has been administered or added up till then--and at least one prostaglandin (C) being added, before, or no later than at, the initiation of the platelet aggregation, so that the initiation and measurement of the platelet aggregation takes place in the presence of the ternary combination of (A), (B), each in the unchanged or in metabolized form, and (C).

Abstract: A combination product containing (A) on the one hand a xanthine derivative of the formula ##STR1## in which one of the radicals R.sup.1 and R.sup.3 represents a straight-chain alkyl, .omega.-1)-oxoalkyl or (.omega.-1)-hydroxyalkyl group having 3 to 8 carbon atoms, and the two other radicals R.sup.2 and R.sup.3, or R.sup.1 and R.sup.2 represent straight-chain or branched alkyl groups having 1 to 8 carbon atoms in the position of R.sup.1 and R.sup.3 and 1 to 4 carbon atoms in the position of R.sup.

Abstract: The present invention relates to a pharmaceutical combination product for the induction of labor or for preventing the development of pregnancy, containing(A) one or more antigestagen(s)(B) one or more long-chain polyunsaturated fatty acid(s) or preparations thereof and, if necessary,(C) prostaglandins,where suitable as antigestagens are all compounds which have a strong affinity for the gestagen receptor but at the same time do not themselves have any considerable intrinsic gestagenic activity.The products are preferably administered intravaginally or (extra)amnially. In this connection, it is possible for the antigestagens and the fatty acids according to the invention to be administered either simultaneously or separately, for example consecutively.

Abstract: A combination product containing (A) on the one hand a xanthine derivative of the formula ##STR1## in which one of the radicals R.sup.1 and R.sup.3 represents a straight-chain alkyl, (.omega.-1)-oxoalkyl or (.omega.-1)-hydroxyalkyl group having 3 to 8 carbon atoms, and the two other radicals R.sup.2 and R.sup.3, or R.sup.1 and R.sup.2 represent straight-chain or branched alkyl groups having 1 to 8 carbon atoms in the position of R.sup.1 and R.sup.3 and 1 to 4 carbon atoms in the position of R.sup.

Abstract: Dispensing packs which contain chambers with at least two solid, not mechanically connected dosage units of various pharmaceuticals.

Abstract: O-acetylsalicylic acid and a pyrimido-pyrimidine as combination products.

Abstract: What are disclosed are: a substance, obtained from blood serum and having a molecular weight below 2000, which is suitable for stabilizing prostaglandins, especially those of the A, E, F, or I type; methods for preparing such a stabilizing substance from blood serum; pharmaceutical preparations containing a prostaglandin or prostaglandin derivative together with such a stabilizing substance; and methods for stabilizing a pharmaceutical preparation containing a prostaglandin or prostaglandin derivative.